1-4 of 4
John F Seymour, MB, BS, PhD, FRACP
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD
Journal: Blood
Blood (2012) 120 (21): 3808.
https://doi.org/10.1182/blood.V120.21.3808.3808
Published: 2012
Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPIā‰„3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP
Journal: Blood
Blood (2012) 120 (21): 2652.
https://doi.org/10.1182/blood.V120.21.2652.2652
Published: 2012
Journal Articles

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Andrew W. Roberts, MBBS, PhD, John F Seymour, MB, BS, PhD, FRACP, Jennifer R Brown, MD, PhD, William G Wierda, Thomas J. Kipps, MD, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Hao Xiong, Ph.D., Yue Cui, PhD, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 883.
https://doi.org/10.1182/blood.V114.22.883.883
Published: 2009
Journal Articles

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

Davi D M Ross, Andrew Grigg, Anthony Schwarer, Christopher Arthur, Kerryn Loftus, Anthony K Mills, Robin Filshie, Ruth Columbus, John Reynolds, John F Seymour, MB, BS, PhD, FRACP, Susan Branford, Timothy Hughes
Journal: Blood
Blood (2008) 112 (11): 1102.
https://doi.org/10.1182/blood.V112.11.1102.1102
Published: 2008